News from NORD
LOS ANGELES – “Durable and persistent” benefit seen in open-label trial of cerliponase alfa in neuronal ceroid lipofuscinosis type 2 disease.
Daily News Podcast
And bum kidneys shouldn’t stop dabigatran reversal.
LOS ANGELES – Members of the AAN Neurology Drug Pricing Task Force spoke about the issues that arise in getting patients access to high-cost drugs...
The bill passed despite opposition from a broad coalition of physician and patient groups.
Hizentra is the first FDA-approved subcutaneously administered human immunoglobulin maintenance therapy for CIDP.
From the Journals
Results cast doubt on the validity of the FDA’s advisory warning in 2006.